41 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Discovery of KDM5A inhibitors: Homology modeling, virtual screening and structure-activity relationship analysis.
Sichuan University
Inhibition of Histone Demethylases Offers a Novel and Promising Approach for the Treatment of Cancer and Other Diseases.
Therachem Research Medilab (India)
Docking and Linking of Fragments To Discover Jumonji Histone Demethylase Inhibitors.
University of Oxford
8-Substituted Pyrido[3,4-d]pyrimidin-4(3H)-one Derivatives As Potent, Cell Permeable, KDM4 (JMJD2) and KDM5 (JARID1) Histone Lysine Demethylase Inhibitors.
The Institute of Cancer Research
Phenyl-quinoline-xxo-butyric Acid Inhibitors of Histone Lysine Demethylase for the Treatment of Cancer.
Arrival Discovery
Discovery of a novel 1H-pyrazole- [3,4-b] pyridine-based lysine demethylase 5B inhibitor with potential anti-prostate cancer activity that perturbs the phosphoinositide 3-kinase/AKT pathway.
Zhengzhou University
Focused Screening Identifies Different Sensitivities of Human TET Oxygenases to the Oncometabolite 2-Hydroxyglutarate.
University of Oxford
Structure-Based Design of Selective Fat Mass and Obesity Associated Protein (FTO) Inhibitors.
University of Oxford
Recent Advances with KDM4 Inhibitors and Potential Applications.
St. Jude Children'S Research Hospital
Discovery of pyrazole derivatives as cellular active inhibitors of histone lysine specific demethylase 5B (KDM5B/JARID1B).
Zhengzhou University
Lysine demethylase 5B (KDM5B): A potential anti-cancer drug target.
Zhengzhou University
Lead optimization of a pyrazolo[1,5-a]pyrimidin-7(4H)-one scaffold to identify potent, selective and orally bioavailable KDM5 inhibitors suitable for in vivo biological studies.
Genentech
Identification of novel lysine demethylase 5-selective inhibitors by inhibitor-based fragment merging strategy.
Kyoto Prefectural University of Medicine
C8-substituted pyrido[3,4-d]pyrimidin-4(3H)-ones: Studies towards the identification of potent, cell penetrant Jumonji C domain containing histone lysine demethylase 4 subfamily (KDM4) inhibitors, compound profiling in cell-based target engagement assays.
Institute of Cancer Research
Design of KDM4 Inhibitors with Antiproliferative Effects in Cancer Models.
Celgene Quanticel Research
From a novel HTS hit to potent, selective, and orally bioavailable KDM5 inhibitors.
Genentech
N-(phenylsulfonyl)benzamides and related compounds as Bcl-2 inhibitors
The Regents of The University of Michigan
Pyrido five-element aromatic ring compound, preparation method therefor and use thereof
Shanghai Haihe Pharmaceutical
Polyfluorinated compounds acting as bruton tyrosine kinase inhibitors
Zhejiang Dtrm Biopharma
Steroidal 5a-reductase inhibitors using 4-androstenedione as substrate.
Metropolitan University-Xochimilco
Roles of phosphate recognition in inositol 1,3,4,5,6-pentakisphosphate 2-kinase (IPK1) substrate binding and activation.
Mcgill University
Cyclohexylamine derivatives having β2 adrenergic agonist and M3 muscarinic antagonist activities
Almirall
A PHGDH inhibitor reveals coordination of serine synthesis and one-carbon unit fate.
Whitehead Institute For Biomedical Research
5-HT3 receptor modulators, methods of making, and use thereof
Albany Molecular Research
Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
Merck Sharp & Dohme